AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ocular Therapeutix Participates in Upcoming Scientific Conferences
ByAinvest
Tuesday, Jul 22, 2025 7:02 am ET1min read
Ocular Therapeutix to participate in upcoming scientific conferences in July and August 2025, including OIS Retina 2025, ASRS 2025, and Women in Ophthalmology (WIO 2025). The company will present on various topics related to drug delivery and retinal disease, including its investigational product candidate AXPAXLI for wet age-related macular degeneration.
Ocular Therapeutix, a leading innovator in retinal disease treatment, has announced its participation in several upcoming scientific conferences in July and August 2025. The company will be presenting on various topics related to drug delivery and retinal disease, including its investigational product candidate AXPAXLI for wet age-related macular degeneration (AMD).Ocular Therapeutix will be showcasing its research and innovations at the OIS Retina 2025 conference, the ASRS 2025 conference, and the Women in Ophthalmology (WIO 2025) conference. These conferences provide a platform for the company to engage with fellow researchers, clinicians, and industry professionals, sharing the latest advancements in retinal disease treatment and drug delivery technologies.
The company's investigational product candidate, AXPAXLI, is designed to address the unmet needs in wet AMD treatment. AXPAXLI is currently being evaluated in a phase 3 clinical trial, SOL-R, which aims to assess the safety and efficacy of the drug in patients with wet AMD. The trial, which recently completed enrollment, will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study [3].
Ocular Therapeutix's participation in these conferences is part of its ongoing commitment to advancing the field of ophthalmology and improving patient outcomes. The company's focus on innovation and collaboration is reflected in its involvement in key scientific events and its dedication to developing novel treatment options for retinal diseases.
References:
[1] https://www.ophthalmologytimes.com/clinical/amd
[2] https://www.ophthalmologytimes.com/clinical/amd
[3] https://www.ophthalmologytimes.com/clinical/amd
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet